Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1645Carcinoma, Renal Cell 505Urinary Bladder Neoplasms 462Carcinoma, Transitional Cell 236Breast Neoplasms 228Kidney Neoplasms 218Neoplasms 194Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 172Ovarian Neoplasms 163Melanoma 163Neoplasm Metastasis 144Lung Neoplasms 128Non-Muscle Invasive Bladder Neoplasms 107Pancreatic Neoplasms 103Stomach Neoplasms 101Uterine Cervical Neoplasms 93Squamous Cell Carcinoma of Head and Neck 86Endometrial Neoplasms 84Carcinoma, Hepatocellular 77Sarcoma 76Esophageal Neoplasms 72Head and Neck Neoplasms 70Triple Negative Breast Neoplasms 67Adenocarcinoma 67Colonic Neoplasms 53Testicular Neoplasms 52Disease 47Wilms Tumor 46Urologic Neoplasms 46

Interventions

radium Ra 223 dichloride 1Pluvicto 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Castrate Resistant Prostate Cancer (mCRPC) × Genitourinary × 1 year × Clear all
NCT04597125 2026-05-11

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

Bayer

Phase 4 Active not recruiting
654 enrolled
Genitourinary

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT06943495 2025-09-09

PRODIGY-2

CHU de Quebec-Universite Laval

Phase 1 Recruiting
60 enrolled
Genitourinary

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡